• Artelo reported interim clinical results for ART27.13, positioning the program as a potential new option for cancer-related anorexia where it says no FDA-approved treatment exists.
• In an interim analysis, patients receiving ART27.13 showed a mean body weight gain of 6.38% versus a -5.42% change for placebo after 12 weeks.
• The company also cited Phase 1 results for ART26.12 that it said support continued development toward chemotherapy-induced peripheral neuropathy, an indication it described as having no approved treatments in the U.S., UK, or EU.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Artelo Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001640334-26-000515), on March 23, 2026, and is solely responsible for the information contained therein.